Research Progress on the Immunosynergistic Mechanism of New Adjuvants for Recombinant Protein Vaccines

DOI: https://doi.org/10.62517/jmhs.202605210

Author(s)

Tianyu Ma*

Affiliation(s)

School of Pharmacy, Qilu Medical University, Zibo, Shandong, China

Abstract

By analyzing the different targets of various types of vaccine adjuvants and traditional aluminum adjuvants, to find an adjuvant that can be biased towards Th1 immune environment to prolong the protection time and protect special groups. The data of new adjuvants that have been successfully used in vaccines were analyzed to compare their safety and reliability. TLR agonists, saponins, emulsions and other adjuvants have significant advantages in the development of long-lasting immunity in special populations.

Keywords

Vaccine, Adjuvant, Safety, Immune Response

References

[1] Takumi Kawasaki, Taro Kawai. Toll-like receptor signaling pathways. Front in Immunol.2014.5. [2] Simon D van Haren, Lakshmi Ganapathi, Ilana Bergelson, David J Dowling, Michaela Banks, Ronald C Samuels, Steven G Reed, Jason D Marshall, Ofer Levy. In vitro cytokine induction by TLR-activating vaccine adjuvants in human blood varies by age and adjuvant. Cytokine. 2016.83.99-109 [3] Steven G Reed, Fan-Chi Hsu,Darrick Carter,Mark T Orr. The science of vaccine adjuvants: advances in TLR4 ligand adjuvants. Current Opinion in Immunology. 2016. 41.85-90 [4] Deepender Kaushik, Arshpreet Kaur, Nikolai Petrovsky, Deepak B Salunke. Structural evolution of toll-like receptor 7/8 agonists from imidazoquinolines to imidazoles. RSC Med. Chem. 2021.12.1065-1120. [5] Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial. Lancet Infect Dis. 2021.21.950-961. [6] Jiayin Xing, Xiangxiang Zhao, Xiaotian Li, Ren Fang, Mingrui Sun, Yang Zhang and Ningning Song.The recent advances in vaccine adjuvants. Front in Immunol. 2025 16. [7] Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol, 2004. 4(4).248-257. [8] Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol, 2002.20.709-760. [9] Caroline R. Champion, Heplisav-B: A Hepatitis B Vaccine With a Novel Adjuvant. Ann Pharmacother.2021.55(6). 783-791. [10] Martijn H den Brok, Christian Bull, Melissa Wassink, Annemarie M de Graafet al. Saponin-based adjuvants induce cross-presentation in dendritic cells by intracellular lipid body formation. NATURE COMMUNICATIONS.2016.7. [11] Lisa M Dunkle, Karen L Kotloff, Cynthia L Gay, German Anez et al. Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. The new england journal of medicine 2022 388(6) 531-543. [12] Zhuanqing Huang, Hui Gong, Qi Sun, Jinjin Yang, Xiaochuan Yan, Fenghua Xu. The Research progress on emulsion vaccine adjuvants. Heliyon. 2024.10 (3) [13] Himal Lal, Anthony L Cunningham, Olivier Godeaux, Roman Chlibek, Javier Diez-Domingo et al .Efficacy of an adjuvantedherpes zoster subunit vaccine in older adults.NEW ENGLAND JOURNAL OF MEDICINE, 2015,372(22).2087-2096 [14] Alberto Papi, Michael G Ison, Joanne M Langley, Dong-Gun Lee et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. NEW ENGLAND JOURNAL OF MEDICINE2023.388(7) 595-608 [15] Darrell J Irvine, Melissa C Hanson, Kavya Rakhra, Talar Tokatlian. Synthetic Nanoparticles for Vaccines and Immunotherapy. CHEMICAL REVIEWS 2015.115(19).11109-11146. [16] Stella Buchhorn de Freitas, Amilton Clair Pinto Seixas Neto, Luciano Aparecido Panagio et al. Biogenic silver nanoparticle as an adjuvant inan S1 subunit recombinant vaccine. BRAZILIAN JOURNAL OF MICROBIOLOGY. 2025.56(2) 757-766. [17] Yanru Shen ,Weijin Huang , Jianhui Nie, Li Zhang Progress Update on STING Agonists as Vaccine Adjuvants Vaccines 2025 13(4)371. [18] Alberta Di Pasquale, Scott Preiss, Fernanda Tavares Da Silva,Nathalie Garcon Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines. 2015, 3, 320-34. [19] Etsuro Nanishi, David J. Dowling, Ofer Levy. Toward precision adjuvants: optimizing science and safety. CURRENT OPINION IN PEDIATRICS.2020.32(1). 125-138.